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Peroxidase-Dependent Metabolism of
Benzene's Phenolic Metabolites and Its
Potential Role in Benzene Toxicity and
Carcinogenicity
by Martyn T. Smith,* Janice W. Yager,*
Karen L. Steinmetz,* and David A. Eastmondt
The metabolism oftwoofbenzene's phenolic metabolites, phenol and hydroquinone, byperoxidase enzymes
has been studied in detail. Studies employing horseradish peroxidase and human myeloperoxidase have shown
that in the presence ofhydrogen peroxide phenol is converted to 4,4'-diphenoquinoneand othercovalent bind-
ing metabolites, whereas hydroquinone is converted solely to 1,4-benzoquinone. Surprisingly, phenol stimu-
lates the latter conversion rather than inhibiting it, an effect that may play a role in the in vivo myelotoxic-
ity ofbenzene. Indeed, repeated coadministration ofphenol and hydroquinone to B6C3F, mice results in a
dramatic and significant decrease in bone marrow cellularity similar to that observed following benzene ex-
posure. A mechanism ofbenzene-induced myelotoxicity is therefore proposed in which the accumulation and
interaction of phenol and hydroquinone in the bone marrow and the peroxidase-dependent formation of
1,4-benzoquinone are important components. This mechanism may also be responsible, at least in part, for
benzene's genotoxic effects, as 1,4-benzoquinone has been shown to damage DNA and is shown here to in-
duce multiple micronuclei in human lymphocytes. Secondary activation ofbenzene's phenol metabolites in
the bone marrow may therefore play an important role in benzene's myelotoxic and carcinogenic effects.
Introduction
Understanding the mechanism by which benzene ex-
erts its toxic and carcinogenic effects on the
hematopoietic system may be essential to determine
whether low-level chronic exposure to benzene poses a
significant health threat. Previous research has shown
that benzene itselfis probably not the actual toxicant, but
is convertedby hepatic metabolism to ametabolite(s) that
travels to the bone marrow and exerts its toxic effects
(1,2). There is, however, also the potential for benzene to
be directly activated within the bone marrow itself (3).
The primary metabolite ofbenzene in vivo is phenol with
hydroquinone, catechol, and trans,trans-muconic acid oc-
curring as significant secondary metabolites (4-6). Fol-
lowing benzene exposure, the three principal phenolic
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metabolites of benzene (Fig. 1) rise in concentration
within the bone marrow (7,8). The rise in phenol is tran-
sient, but hydroquinone and catechol accumulate to rela-
tively high concentrations (8). This selective accumulation
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FIGURE 1. The principal phenolic metabolites formed from benzene.SMITH ETAL.
raises the possibility that a secondary bioactivation ofone
or more ofthese phenolic metabolites may occur within
the bone marrow and generate the actual toxic species.
The bone marrow is an organroughly equivalent in size
with that ofthe liver in which 90% ofthebody'sgranulo-
cytic leukocytes are located (3). These leukocytes are
capable ofundergoing aunique type ofoxidative metab-
olism known as the "oxidative burst" in which numerous
lysosomal and peroxidative enzymes, as well as various
oxidants including H202, are released into phagosomes
and the extracellular space (9,10). One ofthese enzymes,
myeloperoxidase (MPO), accounts for 5% of the dry
weight ofmature peripheral neutrophils and is a signifi-
cant cellular component of bone marrow granulocytic
cells (11). The immature granulocytes located within the
bone marrow have, in fact, been shown to contain more
MPO than their mature circulating counterparts (12). All
three principal phenolic metabolites ofbenzene are poten-
tial substrates forMPO (13). We therefore decided to in-
vestigate the role ofthis enzyme and its release, together
with H202, in the activation ofbenzene's phenolic metabo-
lites during the oxidative burst and its possible role in
benzene hematotoxic effects.
Activation of Phenol by Peroxidases
and Stimulated Human Leukocytes
Phenol has been shown to be agood reducing cofactor
in the reduction of H202 by peroxidases. Early in vitro
studies (14,15) demonstrated that phenol is metabolized
by horseradish peroxidase (HRP) to2,2'-biphenol,4,4'-bi-
phenol and an oxidation product with an UV absorbance
maximum at 400 nm, presumably 4,4'-diphenoquinone.
The HRP-dependent conversion ofphenol to DNA- and
protein-binding metabolites has also been reported by
several investigators (16-18). More recently, studies in
our laboratory (19) have shown that phenol is converted
to covalently binding metabolites during the oxidative
burst of stimulated human leukocytes (Table 1). This
covalent binding is blocked by either catalase and azide,
suggesting roles for both H202 and peroxidases in the
binding process (Table 1).
Table 1. Activation of phenol to covalent binding metabolites
during the phorbol myristate acetate-induced oxidative burst of
human leukocytes.
Treatment
Completeb
+ Catalased
+ Azided
- PMA
Covalent binding,a
nmole phenol equiv./mg protein
2.7 + 1.0'
0.5 + 0.1
0.4 + 0.2
0.1 + 0.05
aConvalent binding to protein was determined after a 20-min
incubation as described in Eastmond et al. (19).
bComplete incubations contained freshly isolated human leukocytes
(10' cells/mL), ["4C] phenol (30 MAM), and PMA (1 Mg/mL) in Dulbecco's
phosphate buffer, pH 7.1, at 370C.
cData from Eastmond et al. (19). Mean ± SD ofthree experiments
are shown.
dCatalase was added at 13,000 U/mL and sodium azide at 10 mM.
We have also shown that extensive phenol binding to
protein occurs very rapidly in the presence of human
MPO and H202, as well as with HRP (20). This binding
is inhibited by the presence ofglutathione or ascorbate,
most likely because oftheir ability to act as antioxidants
and reduce the phenoxy radical back to phenol (Fig. 2)
(20). In our studies, 4,4'-biphenol and4,4'-diphenoquinone
were the principal identifiable products, but it is clear
that 2,2'-biphenol is also formed (Fig. 2). In fact, a poly-
merization product of2,2'-biphenol is likely to be the ma-
jor DNA-binding species formed fromphenol (17,18), with
4,4'-diphenoquinone beingresponsible for a portion ofthe
protein binding observed (20). Both the biphenols and
4,4'-diphenoquinone produce a variety of cytotoxic and
genotoxic effects on human lymphocytes (21) and could
potentially be involved in benzene's in vivo bone marrow
toxicity.
Peroxidase-Dependent Metabolism
of Hydroquinone and the
Stimulating Effect of Phenol
During studies of the peroxidase-dependent metabo-
lism ofphenol (20), it was noted that phenol appeared to
stimulate the metabolism of4,4'-biphenol to 4,4'-dipheno-
quinone. The similarity in structure between
4,4'-biphenol and hydroquinone suggested that phenol
may have a similar effect on the peroxidase-dependent
metabolism ofhydroquinone. Hydroquinone is converted
by a two-electron oxidation to 1,4-benzoquinone in a
stoichimetric fashionby aprocess dependent on the pres-
ence of HRP or MPO and H202 (22). The removal of
hydroquinone during this process is stimulated by the
presence ofphenol (Fig. 3). The concentration ofphenol
mustbe higherthan that ofhydroquinone, but significant
stimulation ofHRP-dependent hydroquinone metabolism
occurs when the phenol to hydroquinone ratio is as low
as 1.33 (Fig. 4A). Much more significant effects are ob-
served however when this ratio rises above 10(Fig. 4A).
With MPO-dependent hydroquinone metabolism, the
picture is slightly more complex. When 0.55 U/mL MPO
is incubated with 75 JAM hydroquinone, concentrations of
phenol below 5 mM have an inhibitory effect on hydro-
quinone removal (Fig. 4B). A significant stimulatory ef-
fect is observed only at phenol concentrations above 10
mM (Fig. 4B). If, however, the MPO and hydroquinone
concentrations are lowered to 0.3 U/mL and 10 JAM,
respectively a significant stimulatory effect is observed
with phenol concentrations as low as 100 ,uM (K. L. Stein-
metz, D. A. Eastmond, and M. T. Smith, manuscript in
preparation). A significant stimulatory effect ofphenol on
MPO-dependent hydroquinone oxidation can therefore be
observed at concentrations that are at least achievable
within the bone marrow in vivo (8).
Similar results to those described, where phenol stimu-
lates the metabolism ofhydroquinone, are also observed
in rodent bone marrow cell cultures and bone marrow
homogenates (23) and in lysates from elicited murine
peritoneal macrophages (24), which contain aperoxidase
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FIGURE 2. Peroxidase-mediated metabolism of phenol to biphenols and 4,4'-diphenoquinone.
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FIGURE 3. Phenol-induced stimulation of hydroquinone metabolism by horseradish peroxidase (A) and human myeloperoxidase (B). Complete in-
cubations consisted of 75 ,IM hydroquinone, 1 mM H202, and variable concentrations of HRP and MPO in 0.1 M phosphate buffer, pH 7.4, at
370C. The reaction was terminated at 2 min by the addition of 5% trichloroacetic acid. Hydroquinone concentration was measured by HPLC
with electrochemical detection as described in Eastmond et al. (22).
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FIGURE 4. Effect of phenol concentration on hydroquinone metabolism by horseradish peroxidase (A) and human myeloperoxidase (B). Incuba-
tions and analyses were performed as described in the legend to Fig. 3 except that 0.06Mg/mL HRP and 0.55 U/mL MPO were used and phenol
was added at different concentrations between 0.1 and 32 mM.
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FIGURE 5. Proposed scheme for the phenol-induced stimulation of
hydroquinone metabolism.
component. The precise mechanism by which phenol
stimulates the oxidation ofhydroquinone is unclear. The
most likely mechanism, however, would involve the en-
zymatic oxidation of phenol to its phenoxy radical that
would then directly oxidize the hydroquinone to its semi-
quinone radical (Fig. 5). The latter is the rate-limiting
step in the overall oxidation of hydroquinone to
1,4-benzoquinone with the quinone species then being
derived from a disproportionation ofthe semiquinone rad-
icals (Fig. 5). This mechanism is consistent with the ob-
servation that phenol is only minimally consumed during
the process (22).
The stimulatory effects ofphenol on hydroquinone ox-
idation suggested that a similar phenomenon may occur
following benzene exposure in vivo. In order to test this
hypothesis, R. Irons ofthe Chemical Industry Institute
of Toxicology administered combinations of benzene's
phenolic metabolites to mice and measured their effect
on bone marrow cellularity. The concomitant administra-
tion ofphenol (75 mg/kg) and hydroquinone (25-75 mg/kg)
to B6C3F I mice twice daily produced a dramatic and sig-
nificant decrease in bone marrow cellularity. Other com-
binations ofthe phenolic metabolites ofbenzene did not
produce similar effects, nor did administration of the
metabolites alone (22).
Benzene
Proposed Mechanism of Benzene-
Induced Myelotoxicity
Thefindings described are consistentwiththeproposed
mechanism for benzene-induced myelotoxicity outlined in
Figure 6. Briefly, the following events seem to be impor-
tant inbenzene-induced myelotoxicity: a) the hepatic con-
version of benzene to phenol and hydroquinone; b) the
selective accumulation of these metabolites in the bone
marrow; c) the localized phenol-dependent stimulation of
hydroquinone oxidation in the bone marrow; and d) the
formation of 1,4-benzoquinone in the bone marrow. Al-
though the phenol-induced stimulation ofhydroquinone
metabolism in the bone marrow can occur in vitro and
may be important in vivo, one cannot also rule out a tox-
icokinetic interaction between these two compounds in
benzene-induced myelotoxicity. An alternative or further
contributing factor in the in vivo toxicity of coad-
ministered phenol and hydroquinone may be that they
compete for conjugating enzymes and co-factors, thereby
raising their free concentration in the plasma, and
presumably the bone marrow, following coadministra-
tion. Studies are presently underway to test the impor-
tance, if any, of this potential toxicokinetic interaction.
The proposed mechanism ofbenzene-induced myelotox-
icity outlined in Figure-6 shows MPO to be the activat-
ing enzyme and 1,4-benzoquinone as the ultimate toxic
metabolite. Two questions are raised immediately by this
scheme: Any peroxidase enzyme is likely to be able to
catalyze the conversion of hydroquinone to 1,4-benzo-
quinone, sowhy is MPO shown as the sole activating en-
zyme? What role, if any, does another putative toxic
metabolite of benzene, i.e., trans,trans-muconaldehyde
(25,26), play since it is omittedfrom this scheme? Clearly
some caveats must be placed on the proposed scheme.
The rodent bone marrow contains atleast two distinct
peroxidases, myeloperoxidase andeosinophilperoxidase,
with different properties (2?). Either of these two en-
zymes could potentially activate hydroquinone, as could
the hydroperoxidase component of prostaglandin syn-
thase (PGS), which may also be present in the bone mar-
row. Recent studies demonstrating thatbenzene-induced
myelotoxicity can be ameliorated by the simultaneous ad-
ministration ofindomethacin (28,29) are suggestive of a
FIGURE 6. Proposed mechanism for benzene-induced myelotoxicity. HQ, hydroquinone; BQ, 1,4-benzoquinone; P450, cytochrome P-450; and MPO,
myeloperoxidase.
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FIGURE 7. Effect of indomethacin on hydroquinone metabolism by
crude(A)and pure(B) human myeloperoxidase. Incubations contained
10 ,uM hydroquinone, 1 mM H202, and either 0.2 (crude) or 0.3 (pure)
U/mL ofmyeloperoxidase in 0.1 phosphate buffer(pH 7.4). All incu-
bations were performed at 370C for 5 min and terminated by addi-
tion oftrichloroacetic acid. Hydroquinone concentration was meas-
ured as described in Eastmond et al. (22).
role for PGS. This drug is a known inhibitor of the cy-
clooxygenase component ofPGS but has no effect on the
hydroperoxidase component ofthis enzyme (30). Not sur-
prisingly, however, these drugs also have numerous non-
specific effects, including inhibitory effects on the oxida-
tive burst ofleukocytes (31) and even the MPO-catalyzed
oxidation of hydroquinone, where both indomethacin
(Fig. 7) and aspirin (data not shown) produce significant
inhibitory effects. Caution must therefore be exercised
in reaching conclusions derived from data employing
these relatively nonspecific agents. The elucidation ofthe
precise roles ofMPO, PGS, and otherperoxidases in the
myelotoxicity of benzene will require further work and
is the subject of continuing research in our laboratory.
The reportedly high levels ofMPO in the bone marrow
(11,12,32) in contrast to the low levels of bone marrow
PGS (33) would lend support, however, to a more impor-
tant role for MPO. In addition, recent experiments have
indicated that addition ofarachidonic acid, the physiolog-
ical substrate for PGS, produces only a minimal increase
irn hydroquinone bindingin human and rodent bone mar-
row in vitro, whereas H202 produces highly significant
increases in the amount of hydroquinone equivalents
bound (D. Ross, personal communication).
1,4-Benzoquinone and trans,trans-
Muconaldehyde as Toxic
Metabolites of Benzene
The peroxidase-dependent generation of 1,4-benzo-
quinone in the bone marrow clearly seems to be impor-
tant for the myelotoxicity observed followingphenol and
hydroquinone coadministration to mice. It may also be
important for benzene's myelotoxic effects, but does not
rule out a role for another putative toxic metabolite of
benzene, i.e., trans,trans-muconaldehyde (25,26). Both
1,4-benzoquinone and trans,trans-muconaldehyde area,f3-
unsaturated diketones and as such may have similar ef-
fects on cells. Some of the known effects of
1,4-benzoquinone are listed in Table 2. Clearly, a similar
list could be generated for trans,trans-muconaldehyde
and one cannot rule out an additive role for these two
toxic species in benzene-induced toxicity and carcinoge-
nicity.
One effect consistently observedfollowingbenzene ex-
posure is the induction ofmicronuclei(34-36). The possi-
bility arises that 1,4-benzoquinone could be responsible
for this effect. To test this hypothesis, cultured human
lymphocytes were exposed to various concentrations of
1,4-benzoquinone for different time periods. In these cul-
tures, we consistently observed a cytotoxic effect on one
subpopulation of cells and no adverse effect on another
subpopulation, which went on to replicate normally (Ta-
ble 3). In another small and highly selective subpopula-
tion, a broad spectrum ofgenetic damage was observed
withthe occurrence ofmultiplemicronuclei(Fig. 8). A cell
with 4 micronuclei is shown in Figure 8, but as many as
11 micronuclei in a single cell can be observed. In the
modified procedure ofFenech and Morley (37) a similar
pattern ofmultiple micronuclei formation is classically ob-
served with microtubule inhibitors, such as colchicine and
vincristine. As 1,4-benzoquinone has also been shown to
Table 2. Biological effects of 1,4-benzoquinone.
Binds to DNA and protein
Interferes with microtubule assembly
Inhibits DNA and RNA sythesis
Causes single-stranded DNA breaks
Causes SCEs in humans lymphocytes in vitro
Causes chromosomal fragmentation during cell division
Inhibits cell division resulting in pyknosis of the
chromosomes during metaphase
Interferes with the growth ofbone marrow stromal cells
Interferes with lymphocyte blastogenesis and agglutination
100 -
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70-
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Table 3. Effect of 1,4-benzoquinone on human lymphocyte
viability and replicative index.'
Time of Replicative
addition, % Viable index,
Treatment hr Male Female female
Control 24 87 82
BQ, 2.5 pM 57 42
BQ, 15pM 31 36 -
Control 38 - 74 1.47
BQ, 2.5 JM - 56 1.42
BQ, 15,M - 37 1.42
Control 41 - 84 1.67
BQ, 2.5 JM - 49 1.65
BQ, 15 JAM - 35 1.86
Control 43 82 - 1.75
BQ, 2.5 AM 51 - 1.71
BQ, 15 JM 30 - 1.65
aHuman lymphocytes were grown in RPM1 culture media with sup-
plements and harvested onto slides at 72 hrfor the measurement of
replicative index. Viability was determined as the exclusion oftrypan
blue. 1,4-Benzoquinone (BQ) was added in DMSO at two different con-
centrations at the time points shown. Control incubations received
DMSO alone.
block the thiol-sensitive GTPbinding site on microtubules
with remarkable potency (38), it is perhaps not surpris-
ing to find such an effect. 1,4-Benzoquinone can also form
DNA adducts and cause strand breaks in DNA (39). It is
also mutagenic, at least in V79 cells (40). One may there-
fore conclude that 1,4-benzoquinone could cause a broad
spectrum of DNA damage in cells, including mutations,
chromosomal breaks, and potentially aneuploidy, and
may be responsible forthe genotoxic and carcinogenic ef-
fects of benzene both in animals and humans.
FIGURE 8. Human binucleated lymphocyte showing four micronuclei af-
ter treatment with 2.5 MM 1,4-benzoquinone (magnification, x500).
Cells weregrown in RPMI culture media with supplements and har-
vested onto slides at 72 hr. Slides were fixed in methanol and stained
with May-Grunewald Giemsa for enumeration ofmicronuclei in 500
binucleated cells per duplicate culture.
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